Allon Therapeutics seeks liquidation after dementia drug flops

Allon Therapeutics has run short on options after the failure of its top candidate in a Phase II/III study last year for a form of dementia called progressive supranuclear palsy. Under Canada's Bankruptcy and Insolvency Act, the Vancouver-based biotech company plans to sell off its assets to Paladin Labs, leaving the company with $900,000 in cash from Paladin and a list of creditors to converge on what is left. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.